These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 31853990

  • 1. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, Hubka M, Rosales J, Lee M, Kennecke H.
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [Abstract] [Full Text] [Related]

  • 2. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.
    Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z.
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 10. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 11. The value of 68 Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series.
    Liu KY, Goldrich DY, Ninan SJ, Filimonov A, Lam H, Govindaraj S, Iloreta AM.
    Head Neck; 2021 Jun 20; 43(6):E30-E40. PubMed ID: 33786927
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors.
    Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E.
    Gastroenterology; 2018 Mar 20; 154(4):998-1008.e1. PubMed ID: 29155309
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 68 Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.
    Lee H, Eads JR, Pryma DA.
    Oncologist; 2021 Jan 20; 26(1):21-29. PubMed ID: 32886441
    [Abstract] [Full Text] [Related]

  • 17. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    Recent Results Cancer Res; 2013 Jan 20; 194():353-71. PubMed ID: 22918768
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.